Cardiotoxicity of anticancer treatments (Q38473331)

3 September 2017

1 reference

title

Cardiotoxicity of anticancer treatments. (English)

1 reference

3 September 2017

Michael S Ewer

1

1 reference

3 September 2017

Steven M Ewer

series ordinal

2

1 reference

3 September 2017

language of work or name

English

0 references

publication date

12 May 2015

1 reference

Nature Reviews Cardiology

3 September 2017

published in

1 reference

3 September 2017

volume

12

1 reference

3 September 2017

issue

9

1 reference

3 September 2017

page(s)

547-558

1 reference

Cardio-oncology/onco-cardiology.

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

A clinicopathologic analysis of adriamycin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

The hibernating myocardium: current concepts, diagnostic dilemmas, and clinical challenges in the post-STICH era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Cardiac complications of chemotherapy: role of biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Fluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: quantitative radiologic assessment and implications for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Adriamycin cardiomyopathy--risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Cardiotoxicity of anticancer treatments: what the cardiologist needs to know

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Deep inspiration breath-hold technique for left-sided breast cancer: An analysis of predictors for organ-at-risk sparing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Protective effects of carvedilol against anthracycline-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Decline in the use of anthracyclines for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Assessment and comparison of acute cardiac toxicity during high-dose cyclophosphamide and high-dose etoposide stem cell mobilization regimens with N-terminal pro-B-type natriuretic peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Cardiotoxicity Associated With High-Dose Cyclophosphamide Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

ErbB2 is essential in the prevention of dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Cancer drugs and the heart: importance and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epider

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) st

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Congestive heart failure is a rare event in patients receiving imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Chemotherapy-induced cardiotoxicity: detection, prevention, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Radiation-associated cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Chemotherapy and QT Prolongation: Overview With Clinical Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Screening for Coronary Artery Disease After Mediastinal Irradiation for Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Ku70 and Rad51 vary in their importance for the repair of doxorubicin- versus etoposide-induced DNA damage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Underestimating cardiac toxicity in cancer trials: lessons learned?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Radiation-induced heart disease: pathologic abnormalities and putative mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Valvular abnormalities detected by echocardiography in 5-year survivors of childhood cancer: a long-term follow-up study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Radiation-induced heart disease: an under-recognized entity?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Fluoropyrimidine-associated cardiotoxicity: revisited

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Troponin I Provides Insight Into Cardiotoxicity and the Anthracycline-Trastuzumab Interaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.65

Effect of anthracycline antibiotics on oxygen radical formation in rat heart

31 March 2020

1 reference

12 December 2020

[Post-radiotherapy pericarditis; a clinical and pathological study of 75 cases]

1 reference

12 December 2020

Different anthracycline derivates for reducing cardiotoxicity in cancer patients

1 reference

12 December 2020

Anthracycline cardiomyopathy monitored by morphologic changes

1 reference

12 December 2020

Mitoxantrone: its development and role in clinical practice

1 reference

12 December 2020

Factors affecting late mortality from heart disease after treatment of Hodgkin's disease

1 reference

12 December 2020

Using cardiac biomarkers and treating cardiotoxicity in cancer

1 reference

12 December 2020

Distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice

1 reference

12 December 2020

Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase

1 reference

12 December 2020

Onco-cardiology: the time has come.

1 reference

12 December 2020

A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRCARDIO.2015.65

1 reference

release_76mpohckn5fmhkfzvvmvdocewa

3 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/76mpohckn5fmhkfzvvmvdocewa

24 November 2022

mapped directly with Wikidata item

1 reference